Clinical Trial Update: Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment [Phase 2, Phase 3]

View source ↗

Summary

Phase II/III study evaluating Tumor Treating Fields (EFE-P100) with docetaxel for stage IV non-small cell lung cancer after progression on platinum-based therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Tumor Treating Fields (EFE-P100) (not specified)

Snippet

Sponsor: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2, Phase 3 | Status: UNKNOWN